Essential technologies keep ClinVio secure and remember your choices. With your permission, Google Analytics helps us improve our public website. Optional Analytics is off until you choose.
Cookie Policy · Privacy Policy. You can change your choice at any time using Cookie preferences.
Explore global clinical trial activity by specialty, country, phase, and therapeutic area. Create your ClinVio™ profile to be considered for clinical trial adjudication, medical review, advisory, and specialist-support opportunities.
Clinical Trial Index
Figures in this overview cover the full indexed collection, not just the latest 500 trial records displayed below. Recruiting trials are included in the total.
35,557
Total Trials Indexed
31,327
Recruiting Trials Indexed
26
Medical Specialties
163
Countries
4,239
Phase II Trials
1,828
Phase III Trials
+4,555
Added (30 days)
Public registry records · source shown on every trial
35,557 trials indexed · showing the latest 500
Showing 1–12 of 500 matching in the latest 500 indexed
This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
TME remains standard treatment for rectal cancer. Both Robotic TME and taTME are innovative surgical techniques with potential advantages in low rectal cancer. To date, no clinical studies have directly compared the conversion and complication rates between taTME and RTME in this population. Therefore, the investigators propose to conduct a prospective, randomized, parallel-controlled clinical trial comparing taTME with RTME for low rectal cancer, aiming to provide high-level evidence for surgical decision-making and benefit more patients.
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD. You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.
This cross-sectional online survey investigates the prevalence of orofacial pain, sleep-related problems, and oral health-related quality of life (OHRQoL) among adult musicians who play in German amateur orchestras. Participants complete a single, anonymous, approximately 10-minute questionnaire covering demographic data, orofacial pain, sleep bruxism, perceived stress, sleep quality, and the German short version of the Oral Health Impact Profile (OHIP-14). The study examines whether these outcomes differ between instrument groups (woodwind, brass, string, percussion, and other instruments). The primary hypothesis is that players of wind instruments (woodwind and brass) more frequently report orofacial pain and experience a different OHRQoL than players of other instrument groups. The study has a pilot character and aims to generate data to inform future research and targeted dental care concepts for this population.
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Several millions of patients are admitted to ICUs in Europe or USA each year. We and others, have shown that patients discharged from intensive care units (ICU) have a high incidence of cardiovascular and/or renal events and high mortality rate (22%) during the year following ICU discharge. Furthermore, a very recent meta-analysis found an excess hazard of late cardiovascular events which persists for at least 5 years following hospital discharge in sepsis survivors. Hence, many international ICU societies recommended investigating and improving post-ICU outcome with scarce guidance. We demonstrated that the proportion of ICU patients dying or presenting cardiovascular events within the year following ICU discharge is reported \~25% \[2\], reaching \~40% in some studies when considering patients with acute kidney injury (AKI). Plasma biomarkers at ICU discharge have good predictive value and patients with increased kidney or cardiovascular biomarkers display high risk of such events. In addition, we and others demonstrated that AKI or sub-AKI (patient not meeting the AKI definition but with an increased kidney related biomarker) could induce remote cardio-vascular injury and fibrosis, which may be involved in the poor long-term prognosis of ICU-acquired AKI. We hypothesize that strategy that prevent worsening in cardiovascular and/or renal injuries and/or in cardiovascular consequences of sub-AKI and AKI after ICU discharge improve long-term outcomes in ICU survivors. SGLT2 inhibitors are widely recognized as key drugs to protect the kidney and/or the myocardium in chronic diseases such as diabetes or heart failure. Cardio protective effect of SGLT2 inhibitors is optimal in patients with higher cardiac biomarker.
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up
To ensure the care of people with severe asthma continues to improve, it is essential we have detailed information on the health and treatment of as many people with the condition as possible. The purpose of the registry is to gather this information and track the progress of patients and how well they are responding to treatment. Medical research using data from the registry will provide a better understanding of asthma and help to develop and improve the care and treatment for patients with asthma. Detailed protocol can be referred to the reference in this trial registration (International severe asthma registry \[ISAR\]: protocol for a global registry).
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include eye drops, laser treatment, and surgery that help lower eye pressure. However, they do not work for everyone, and the disease may continue to worsen over time. Researchers are looking for better ways to treat open-angle glaucoma. This is an early development study of ASP2767 in people with open-angle glaucoma. In this study, ASP2767 will be given to humans for the first time. ASP2767 is a type of treatment called gene therapy. Gene therapy uses a tool called a vector. In this study a harmless virus is used as the vector. The vector delivers genes into specific parts of the body like the eyes. Once in the eyes these genes help nerve cells in the retina make proteins. These proteins are designed to protect the nerves in the eyes and may help slow down or prevent vision loss. The main aims of the study are to check the safety of ASP2767 in people with open-angle glaucoma, how well they tolerate it, and to find the highest dose of ASP2767 people can safely receive. In addition, the study will also look at the effect of ASP2767 on vision in people with open-angle glaucoma. The study has 2 phases. In both phases of the study, ASP2767 will be given as a single injection into one eye only. In phase 1, small groups of people with open-angle glaucoma will receive ASP2767 starting with lower doses and increasing to higher doses in later groups. The people in the study will also receive prophylactic medicines which will help reduce the risk of inflammation after receiving the ASP2767 injection. Phase 1 is an open-label study. This means that people in the study and the researchers will know which treatment people are getting. Any medical problems people have at each dose level in this study will be recorded. This will help find the highest dose of ASP2767 that people can safely receive, which will also be used in phase 2. In phase 2, another larger group of people with open-angle glaucoma will be randomly placed in 1 of 3 groups of equal size. This means each person will have an equal chance of being placed in any of the 3 groups. They will receive either the highest dose of ASP2767 that people safely received in phase 1, or a slightly lower dose of ASP2767, or a sham injection. A sham injection is a procedure that mimics the injection but does not deliver ASP2767 into the eye. To reduce the risk of inflammation due to the injection, people in the study will also receive a prophylactic medicine or placebo depending on the group they are in. The placebo will look like the prophylactic medicine and will be given in a similar way but will not have any active medicine in it. Researchers use sham injections and placebo to make sure any effect they see in people who take ASP2767 is actually caused by the drug. Phase 2 is a double-masked study, meaning neither the people in the study, nor the researchers will know who is given which treatment. All the people in phase 1 and phase 2 will be followed up for about 1 year after receiving the treatment. After receiving their ASP2767 injection, people will visit the clinic on certain days to have health checks. They will also have their vision checked using different eye tests and will give regular blood and urine samples.
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).
Trial Activity by Specialty
Top eight specialties among the latest 500 trial records displayed on this page. Counts reflect this sample, not all 35,557 indexed trials.
How ClinVio Works
ClinVio is more than a trial listing — it is the path from interest to engagement.
Browse indexed trials by specialty, country, phase, and therapeutic area to see where specialist engagement is happening.
Add your specialization, experience, credentials, and availability. Takes only a few minutes.
ClinVio matches your profile to clinical trial adjudication, medical review, advisory, and specialist-support opportunities.
Engage on flexible terms with sponsors and CROs, contribute your expertise, and receive compensation.
Why Doctors Join ClinVio
No guaranteed placements or income promises — just relevant opportunities and operational support.
Engagements may range from occasional case reviews to ongoing monthly work. Remote options depend on the role.
Engage with sponsors and CROs running trials across multiple countries and therapeutic areas.
Hourly, per-case, or monthly compensation models based on the type and duration of engagement.
Your professional information is encrypted in transit and accessed only with role-based permissions.
Receive notifications when new trials match your specialty, phase, and country preferences.
Our team supports onboarding, contracting, and ongoing engagement logistics end-to-end.
Find medical experts for clinical trial adjudication, medical review, advisory, and specialist-support roles.
Trust, Privacy & Security
Explore the safeguards used to protect professional information and the status of our privacy and security program.
All data in transit is encrypted using modern TLS standards.
Doctor profile data is only exposed to authorized sponsors after approval.
Profile sharing follows a staged disclosure model with consent tracking.
We follow privacy workflows intended to align with GDPR principles.
Profile views and key data access events are logged for accountability.
Governance policies and security assessments are documented in the Trust Center.
ClinVio connects medical specialists with sponsors and CROs for clinical trial adjudication, medical review, advisory, and specialist-support engagements.
Submit the doctor registration request with your name, email, country, primary specialty and professional background. The ClinVio team reviews your details and emails your login details within 2 working days.
Open doctor registrationNo. Public trial records describe clinical trial activity. A ClinVio engagement depends on a specific requirement, matching, review and agreement with the relevant parties.
The doctor and company portals support engagement contracts, time recording, timesheet review and payment tracking. Compensation and work expectations are set through the applicable engagement and contract.
The Trust Center links to ClinVio privacy, security and compliance information, including how to report security concerns.
Visit the Trust CenterClinVio Blog
Explore clinical research roles, specialist opportunities and practical guides for doctors.
ClinVio InsightsHow medical specialists can contribute through adjudication, expert review, medical monitoring and advisory engagements, and how to join ClinVio.
Send your registration request in a few minutes. Once approved, usually within 2 working days, you'll start receiving relevant clinical trial opportunity alerts.
Create Your Doctor Profile